These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23534242)

  • 1. [Connective tissue diseases: news in therapy, role of biologics agents].
    Aubry-Rozier B; Fabreguet I
    Rev Med Suisse; 2013 Mar; 9(377):556, 558-60. PubMed ID: 23534242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sjögren syndrome and systemic lupus erythematosus are distinct conditions.
    Scheinfeld N
    Dermatol Online J; 2006 Jan; 12(1):4. PubMed ID: 16638372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical treatment of connective tissue disease.
    Ciavaglia SJ; Costello PB; Panara N
    Ear Nose Throat J; 1987 Nov; 66(11):457-62. PubMed ID: 3443075
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recent advances in diagnosis and treatment of connective tissue diseases].
    Lorenz HM
    Dtsch Med Wochenschr; 2011 Apr; 136(14):710-2. PubMed ID: 21448833
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab and lupus interstitial lung disease: friend or foe?
    Efthimiou P; Kukar M; Hersh A
    Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of connective tissue diseases with biological agents].
    So A
    Rev Med Suisse; 2008 Mar; 4(149):707-8, 710. PubMed ID: 18472731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxycholoroquine-induced hyperpigmentation.
    Mir A; Boyd KP; Meehan SA; McLellan B
    Dermatol Online J; 2013 Dec; 19(12):20723. PubMed ID: 24365014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell depletion and repopulation in autoimmune diseases.
    Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of myasthenia gravis and connective tissue diseases--the role of Sjøgren's syndrome.
    Yasuda M; Nobunaga M
    Fukuoka Igaku Zasshi; 1994 Feb; 85(2):38-51. PubMed ID: 8144128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome.
    Skudalski L; Shahriari N; Torre K; Santiago S; Bibb L; Kodomudi V; Grant-Kels JM; Lu J
    J Am Acad Dermatol; 2022 Jul; 87(1):1-18. PubMed ID: 35202775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and regression within primary Sjögren's syndrome.
    Manthorpe R; Bredberg A; Henriksson G; Larsson A
    Scand J Rheumatol; 2006; 35(1):1-6. PubMed ID: 16467033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Will targeting B cells be the answer for Sjögren's syndrome?
    Looney RJ
    Arthritis Rheum; 2007 May; 56(5):1371-7. PubMed ID: 17469093
    [No Abstract]   [Full Text] [Related]  

  • 13. Musculoskeletal Manifestations of Non-RA Connective Tissue Diseases: Scleroderma, Systemic Lupus Erythematosus, Still's Disease, Dermatomyositis/Polymyositis, Sjögren's Syndrome, and Mixed Connective Tissue Disease.
    Jacques T; Sudoł-Szopińska I; Larkman N; O'Connor P; Cotten A
    Semin Musculoskelet Radiol; 2018 Apr; 22(2):166-179. PubMed ID: 29672805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The connective tissue diseases and the overall influence of gender.
    Lahita RG
    Int J Fertil Menopausal Stud; 1996; 41(2):156-65. PubMed ID: 8829695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification and molecular characterization of regulatory T cells in connective tissue diseases.
    Banica L; Besliu A; Pistol G; Stavaru C; Ionescu R; Forsea AM; Tanaseanu C; Dumitrache S; Otelea D; Tamsulea I; Tanaseanu S; Chitonu C; Paraschiv S; Balteanu M; Stefanescu M; Matache C
    Autoimmunity; 2009 Jan; 42(1):41-9. PubMed ID: 18800250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of B lymphocyte stimulator inhibitor belimumab may be associated with a decrease in the serum concentration of epidermal growth factor in patients with primary Sjögren's syndrome.
    Kadavath S; Bobic S; Efthimiou P
    Clin Rheumatol; 2015 Sep; 34(9):1651-2. PubMed ID: 25652332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A
    Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurologic manifestations of connective tissue disease.
    Nadeau SE
    Neurol Clin; 2002 Feb; 20(1):151-78, vi. PubMed ID: 11754305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy in primary Sjögren's syndrome.
    Alcântara C; Gomes MJ; Ferreira C
    Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cells and the loss of immunologic tolerance in Sjögren's syndrome and systemic lupus erythematosus.
    Hoffman RW
    Arthritis Rheum; 2007 Oct; 56(10):3180-2. PubMed ID: 17907162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.